Eli Lilly’s run of near-weekly acquisitions still shows no sign of letting up, with the Big Pharma now buying Ajax ...
Eli Lilly continued its recent buying spree, agreeing to pay up to $2.3 billion for Ajax Therapeutics in a deal that bolsters the drugmaker's blood-cancer portfolio. Eli Lilly on Monday said Ajax is ...
Eli Lilly to acquire Ajax Therapeutics for up to $2.3B, boosting blood cancer pipeline with a Phase 1 JAK2 inhibitor for ...
Eli Lilly continued its recent buying spree, agreeing to pay up to $2.3 billion for Ajax Therapeutics in a deal that bolsters the drugmaker’s blood-cancer portfolio.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results